
Strides Shasun receives USFDA approval for Ibuprofen OTC Tablets

Product further strengthens Strides Ibuprofen franchise for the US markets

Bangalore, July 2, 2018 Strides Shasun Limited today announced that it's wholly owned subsidiary Strides Pharma Global Pte. Ltd. has received final approval for ***Ibuprofen Tablets USP, 200 mg (OTC)*** from the United States Food & Drug Administration (US FDA). Ibuprofen Tablets 200 mg (OTC) is a generic version of Motrin® IB Tablets, 200 mg, of Johnson & Johnson Consumer, Inc.

The approval further strengthens Strides Ibuprofen franchise for the US markets that now comprises of 7 approved products addressing a combined Rx and OTC opportunity of US\$ 900 Mn as per IMS and IRi data. The product will be manufactured at the Company's Oral dosage facility at Puducherry and will be marketed by Strides Pharma Inc. in the US Market.

The company has 75 cumulative ANDA filings with US FDA of which 51 ANDAs have been approved as of date and 24 are pending approval.

About Ibuprofen Tablets

Ibuprofen is used to relieve pain from various conditions such as headache, dental pain, muscle aches, or arthritis. It is also used to reduce fever and to relieve minor aches and pain due to the common cold or flu. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID).

About Strides Shasun

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is global pharmaceutical Company headquartered in Bangalore. The Company has two business verticals, viz., Regulated Markets and Emerging Markets.



The Company has global manufacturing footprint with 7 manufacturing facilities spread across three continents including 5 US FDA approved facilities and 2 facilities for the emerging markets. The Company has strong R&D infrastructure in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company's website at www.stridesarco.com

For further information, please contact:

<p><u>Strides</u></p> <p>Badree Komandur, Executive Director +91 80 6784 0747</p> <p><u>Investors:</u></p> <p>Kannan. N: +91 98450 54745 Vikesh Kumar: +91 80 6784 0827 Sandeep Baid : +91 80 6784 0791</p> <p>Strides Shasun Limited CIN : L24230MH1990PLC057062 Regd. Office: 201, 'Devavrata', Sector – 17, Vashi, Navi Mumbai – 400 703 Email: investors@stridesshasun.com</p>	<p><u>PR Consultancy</u></p> <p>Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com</p> <p>K Priya: +91 9535425418 priya@fortunapr.com</p>
---	--

